抗不整脈薬の市場規模、シェア、動向分析レポート：薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

抗不整脈薬市場の成長と動向

世界の抗不整脈薬市場規模は2030年に16億米ドルに達すると予測され、2025～2030年にかけてCAGR 6.35％で成長すると予測されます。

この予測成長は、心血管疾患（CVDs）の有病率の上昇、世界人口の高齢化、医薬品開発の進歩、規制当局の支援、心血管の健康改善を目的とした政府の取り組みなど、相互に関連する複数の要因によってもたらされます。世界保健機関（WHO）によると、CVDは世界の死因の第1位であり、年間約1,790万人が死亡しています。

さらに、高齢化も市場拡大の大きな要因となっています。米国国勢調査局によると、2030年までに米国人口の約20％が65歳以上になると報告されています。この人口動態の変化により、不整脈を含む心血管系の疾患が増加し、抗不整脈薬の需要が高まると予想されます。高齢になるにつれて心臓疾患の開発リスクは高まり、継続的な治療・管理戦略が必要となります。この動向は米国に限ったことではなく、多くの先進国や開発途上国でも同様の人口動態の変化が生じており、その結果、抗不整脈薬に対する需要が世界的に高まっています。

最近の薬剤開発の動向は、市場の成長をさらに後押ししています。抗不整脈薬のセグメントにおける調査と技術革新は、新規化合物や治療アプローチの導入につながっています。例えば、特定のイオンチャネルを標的とする新薬製剤の開発により、これらの薬剤の有効性と安全性プロファイルが改善されています。さらに、個別化医療と薬理ゲノミクスの進歩により、個々の患者のプロファイルに基づいて薬効を最適化するオーダーメイドの治療戦略への道が開かれつつあります。このような技術革新は、治療成績を向上させるだけでなく、医療従事者の抗不整脈療法の採用を促進しています。

抗不整脈薬市場のレポートハイライト

• 薬剤クラス別では、β遮断薬が2024年に34.80%の最大売上シェアを占めました。心拍数の低下や血圧のコントロールに有効であることから、これらの疾患の治療の要となっています。
• 投与経路別では、経口剤が2024年に約71.0%と最大の売上シェアを占めました。経口製剤は、患者が自宅で治療を自己管理できるため、侵襲的な処置や通院の必要性がなく、心房細動や心室頻拍などの慢性疾患の管理に特に魅力的です。
• 流通チャネル別では、2024年の抗不整脈薬の世界市場において、病院薬局セグメントが約60.53％の最大売上シェアを占めています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗不整脈薬市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 抗不整脈薬市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 抗不整脈薬市場：薬剤クラス別、推定・動向分析

• 抗不整脈薬市場：薬剤クラスダッシュボード
• 抗不整脈薬市場：薬剤クラスの変動分析
• 抗不整脈薬市場：薬剤クラス別、収益別
• ナトリウムチャネル遮断薬
• カリウムチャネル遮断薬
• カルシウムチャネル遮断薬
• その他

第5章 抗不整脈薬市場：投与経路別、推定・動向分析

• 抗不整脈薬市場：投与経路ダッシュボード
• 抗不整脈薬市場：投与経路の変動分析
• 投与経路別収益
• 経口
• 非経口
• その他

第6章 抗不整脈薬市場：流通チャネル別、推定・動向分析

• 抗不整脈薬市場：流通チャネルダッシュボード
• 流通チャネル別、収益
• 病院薬局
• 小売薬局
• その他

第7章 抗不整脈薬市場：薬剤クラスによる地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店とチャネルパートナー一覧
  • 主要企業の市場シェア分析、2024年
  • Pfizer
  • Novartis
  • Mylan
  • Baxter International
  • Sanofi
  • GlaxoSmithKline
  • Mayne Pharma
  • Upsher-Smith Laboratories
  • Amomed Pharma
  • Merck

List of Tables

• Table 1 List Of Abbreviation
• Table 2 North America Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 3 North America Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 4 North America Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 5 North America Antiarrhythmic Drugs Market, Distribution Channel, 2018 - 2030 (USD Million)
• Table 6 U.S. Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 7 U.S. Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 8 U.S. Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 9 Canada Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 10 Canada Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 11 Canada Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 Mexico Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 13 Mexico Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 14 Mexico Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Europe Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 16 Europe Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 17 Europe Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 18 Europe Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 19 Germany Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 20 Germany Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 21 Germany Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 UK Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 23 UK Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 24 UK Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 France Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 26 France Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 27 France Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Italy Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 29 Italy Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 30 Italy Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 Spain Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 32 Spain Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 33 Spain Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Denmark Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 35 Denmark Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 36 Denmark Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Sweden Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 38 Sweden Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 39 Sweden Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 Norway Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 41 Norway Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 42 Norway Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 China Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 48 China Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 49 China Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 Japan Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 51 Japan Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 52 Japan Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 India Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 54 India Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 55 India Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 South Korea Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 57 South Korea Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 58 South Korea Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 59 Australia Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 60 Australia Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 61 Australia Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 62 Thailand Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 63 Thailand Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 64 Thailand Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 65 Latin America Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 66 Latin America Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 67 Latin America Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 68 Latin America Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 Brazil Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 70 Brazil Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 71 Brazil Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 72 Argentina Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 73 Argentina Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 74 Argentina Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 75 MEA Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 76 MEA Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 77 MEA Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 78 MEA Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 South Africa Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 80 South Africa Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 81 South Africa Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 85 UAE Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 86 UAE Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 87 UAE Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 88 Kuwait Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 89 Kuwait Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 90 Kuwait Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Antiarrhythmic Drugs Market: Market Outlook
• Fig. 14 Antiarrhythmic Drugs Competitive Insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Antiarrhythmic Drugs Market Driver Impact
• Fig. 18 Antiarrhythmic Drugs Market Restraint Impact
• Fig. 19 Antiarrhythmic Drugs Market Strategic Initiatives Analysis
• Fig. 20 Antiarrhythmic Drugs Market: Drug Class Movement Analysis
• Fig. 21 Antiarrhythmic Drugs Market: Drug Class Outlook And Key Takeaways
• Fig. 22 Sodium Channel Blockers market estimates and forecast, 2018 - 2030
• Fig. 23 Beta Blockers market estimates and forecast, 2018 - 2030
• Fig. 24 Potassium Channel Blockers market estimates and forecast, 2018 - 2030
• Fig. 25 Calcium Channel Blockers market estimates and forecast, 2018 - 2030
• Fig. 26 Other market estimates and forecast, 2018 - 2030
• Fig. 27 Antiarrhythmic Drugs Market: Route of Administration Movement Analysis
• Fig. 28 Antiarrhythmic Drugs Market: Route of Administration Outlook And Key Takeaways
• Fig. 29 Oral market estimates and forecast, 2018 - 2030
• Fig. 30 Parenteral market estimates and forecast, 2018 - 2030
• Fig. 31 Other market estimates and forecast, 2018 - 2030
• Fig. 32 Antiarrhythmic Drugs Market: Distribution Channel Movement Analysis
• Fig. 33 Antiarrhythmic Drugs Market: Distribution Channel Outlook And Key Takeaways
• Fig. 34 Hospital Pharmacies market estimates and forecast, 2018 - 2030
• Fig. 35 Retail Pharmacies market estimates and forecast, 2018 - 2030
• Fig. 36 Other market estimates and forecast, 2018 - 2030
• Fig. 37 Antiarrhythmic Drugs Market: Regional Movement Analysis
• Fig. 38 Antiarrhythmic Drugs Market: Regional Outlook And Key Takeaways
• Fig. 39 Antiarrhythmic Drugs market share and leading players
• Fig. 40 North America, by country
• Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 U.S. key country dynamics
• Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Canada key country dynamics
• Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Mexico key country dynamics
• Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 UK key country dynamics
• Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Germany key country dynamics
• Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 France key country dynamics
• Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Italy key country dynamics
• Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Spain key country dynamics
• Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Denmark key country dynamics
• Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Sweden key country dynamics
• Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Norway key country dynamics
• Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 China key country dynamics
• Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Japan key country dynamics
• Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 India key country dynamics
• Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Thailand key country dynamics
• Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 South Korea key country dynamics
• Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Australia key country dynamics
• Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Brazil key country dynamics
• Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Argentina key country dynamics
• Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 South Africa key country dynamics
• Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Saudi Arabia key country dynamics
• Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 UAE key country dynamics
• Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Kuwait key country dynamics
• Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Market share of key market players- Antiarrhythmic Drugs market

Antiarrhythmic Drugs Market Growth & Trends:

The global antiarrhythmic drugs market size is expected to reach USD 1.6 billion in 2030 and is projected to grow at a CAGR of 6.35% from 2025 to 2030. This anticipated growth is driven by multiple interrelated factors, including the rising prevalence of cardiovascular diseases (CVDs), an aging global population, advancements in drug development, regulatory support, and government initiatives aimed at improving cardiovascular health. According to the World Health Organization (WHO), CVDs are the leading cause of death globally, responsible for approximately 17.9 million deaths annually.

Furthermore, the aging population is a significant factor contributing to market expansion. The U.S. Census Bureau reports that by 2030, approximately 20% of the U.S. population will be 65 years or older. This demographic shift is expected to lead to an increase in cardiovascular conditions, including arrhythmias, thereby heightening the demand for antiarrhythmic drugs. As people age, their risk of developing heart conditions increases, necessitating ongoing treatment and management strategies. This trend is not limited to the U.S.; many developed and developing nations are experiencing similar demographic changes, resulting in a global increase in demand for antiarrhythmic therapies.

Recent advancements in drug development are further propelling market growth. Research and innovation in the field of antiarrhythmic drugs have led to the introduction of novel compounds and therapeutic approaches. For instance, the development of new drug formulations that target specific ion channels has improved the efficacy and safety profiles of these medications. Moreover, advances in personalized medicine and pharmacogenomics are paving the way for tailored treatment strategies that optimize drug efficacy based on individual patient profiles. Such innovations not only enhance treatment outcomes but also encourage the adoption of antiarrhythmic therapies among healthcare providers.

Antiarrhythmic Drugs Market Report Highlights:

• By drug class, the beta blockers segment accounted for the largest revenue share of 34.80% in 2024. Their efficacy in reducing heart rate and controlling blood pressure has made them a cornerstone in the treatment of these disorders.
• Based on route of administration, the oral segment accounted for the largest revenue share of around 71.0% in 2024. Oral formulations allow patients to self-administer treatments at home, eliminating the need for invasive procedures or hospital visits, which can be particularly appealing in managing chronic conditions such as atrial fibrillation and ventricular tachycardia.
• Based on distribution channels, the hospital pharmacies segment accounted for the largest revenue share of around 60.53% in global market for antiarrhythmic drugs in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class Outlook
  • 2.2.2. Route of Administration
  • 2.2.3. Distribution Channel
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Antiarrhythmic Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Cardiovascular Diseases
    • 3.2.1.2. Advancements in Drug Development
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Drug Class Cost
    • 3.2.2.2. Competition from Alternative Therapies
• 3.3. Antiarrhythmic Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Antiarrhythmic Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Antiarrhythmic Drugs Market: Drug Class Dashboard
• 4.2. Antiarrhythmic Drugs Market: Drug Class Movement Analysis
• 4.3. Antiarrhythmic Drugs Market by Drug Class, Revenue
• 4.4. Sodium Channel Blockers
  • 4.4.1. Sodium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Potassium Channel Blockers
  • 4.5.1. Potassium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Calcium Channel Blockers
  • 4.6.1. Calcium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antiarrhythmic Drugs Market: Route of Administration Estimates & Trend Analysis

• 5.1. Antiarrhythmic Drugs Market: Route of Administration Dashboard
• 5.2. Antiarrhythmic Drugs Market: Route of Administration Movement Analysis
• 5.3. Antiarrhythmic Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Oral
  • 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Parenteral
  • 5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antiarrhythmic Drugs Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Antiarrhythmic Drugs Market: Distribution Channel Dashboard
• 6.2. Antiarrhythmic Drugs Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
• 6.3. Hospital Pharmacies
  • 6.3.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Retail Pharmacies
  • 6.4.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Other
  • 6.5.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antiarrhythmic Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Route of Administration, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Vendor Landscape
  • 8.2.1. List of key distributors and channel partners
  • 8.2.2. Key company market share analysis, 2024
  • 8.2.3. Pfizer
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Novartis
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Mylan
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Baxter International
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Sanofi
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. GlaxoSmithKline
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Mayne Pharma
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Upsher-Smith Laboratories
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Amomed Pharma
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Product benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. Merck
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Product benchmarking
    • 8.2.12.4. Strategic initiatives